drugset
drugset / Trial / NCT01068847

Drug Discrimination in Methadone-Maintained Humans Study 3

NCT01068847 ↗

Phase 1 Completed 9 enrolled University of Arkansas National Institute on Drug Abuse (NIDA) · collab
NaSingle-groupDouble-blindBasic science

Summary

This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the participant's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each participant will receive 2-4 of the listed interventions.

Timeline

Start
2010-02
Primary completion
2012-10
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cycloserine Small molecule 500 mg Oral
Subject Cycloserine Small molecule 675 mg Oral
Subject Cycloserine Small molecule 750 mg Oral
Subject Naloxone Small molecule 0.15 mg/kg Intramuscular
Subject Naloxone Small molecule 0.2 mg/kg Intramuscular
Subject Nifedipine Other / unclassified 10 mg Oral
Subject Nifedipine Other / unclassified 20 mg Oral
Subject Tizanidine Small molecule 4 mg Oral
Subject Tizanidine Small molecule 8 mg Oral
Subject Tizanidine Small molecule 12 mg Oral
Subject Verapamil Other / unclassified 30 mg Oral
Subject Verapamil Other / unclassified 60 mg Oral
Subject Verapamil Other / unclassified 120 mg Oral

Indications

drug dependence